Topiramate (Topamax) for prevention of migraine.
Topiramate is the second antiepileptic drug, after valproate, to be approved by the FDA for prevention of migraine. There is no evidence that it is more effective than a beta-blocker for this indication, and it is much more expensive. Topiramate can cause cognitive impairment and weight loss. No studies have compared it to valproate for this indication.
D000927:Anticonvulsants / Q000009:adverse effects / Q000627:therapeutic use*; D003072:Cognition Disorders / Q000139:chemically induced; D005632:Fructose / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D006801:Humans; D008881:Migraine Disorders / Q000517:prevention & control*; D000077236:Topiramate; D015431:Weight Loss / Q000187:drug effects
D000927:Anticonvulsants; D000077236:Topiramate; D005632:Fructose